Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903921 | 1.00 | SLC6A4 (0.55) | SLC6A4SLC6A3KDM1AMAOAMAOB | |
| SCHEMBL13125707 | 0.83 | SLC6A4 (0.44) | SLC6A4SLC6A3KDM1AMAOAMAOB | |
| SCHEMBL3649072 | 0.83 | SLC6A3 (0.49) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL8726217 | 0.82 | SLC6A3 (0.48) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL8726215 | 0.82 | SLC6A3 (0.48) | SLC6A4SLC6A3 | |
| SCHEMBL13093193 | 0.80 | SLC6A3 (0.55) | SLC6A4SLC6A3 | |
| SCHEMBL13093030 | 0.80 | SLC6A3 (0.55) | SLC6A4SLC6A3 | |
| SCHEMBL5972686 | 0.79 | SLC6A2 (0.39) | SLC6A4SLC6A3 | |
| SCHEMBL13093209 | 0.79 | TP53 (0.46) | SLC6A4SLC6A3 | |
| SCHEMBL13093211 | 0.78 | SLC6A3 (0.45) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486193-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | AVENTISUB INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1150951-A1 | 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000040553-A1 | 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | MMP3, MMP1, MMP9 | SLC6A4 3995/4885SLC6A3 2953/4885KDM1A 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.